BR0200751C1 - processo de preparação de formulações de semicarbazonas e/ou tiossemicarbazonas com ciclodextrinas e seus derivados e produtos obtidos desse processo - Google Patents

processo de preparação de formulações de semicarbazonas e/ou tiossemicarbazonas com ciclodextrinas e seus derivados e produtos obtidos desse processo

Info

Publication number
BR0200751C1
BR0200751C1 BRC10200751-7A BR0200751A BR0200751C1 BR 0200751 C1 BR0200751 C1 BR 0200751C1 BR 0200751 A BR0200751 A BR 0200751A BR 0200751 C1 BR0200751 C1 BR 0200751C1
Authority
BR
Brazil
Prior art keywords
derivatives
cyclodextrins
products obtained
formulations
preparing
Prior art date
Application number
BRC10200751-7A
Other languages
English (en)
Other versions
BRPI0200751B1 (pt
BR0200751A (pt
Inventor
Heloisa De Oliveira Beraldo
Ruben Dario Sinisterra
Maria Carolina Doretto
Rafael Pinto Vieira
Marcio De Matos Coelho
Leticia Regina De Sou Teixeira
Original Assignee
Univ Minas Gerais
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minas Gerais filed Critical Univ Minas Gerais
Priority to BRPI0200751A priority Critical patent/BRPI0200751B1/pt
Priority to AU2003227141A priority patent/AU2003227141A1/en
Priority to CA002475493A priority patent/CA2475493A1/en
Priority to US10/503,735 priority patent/US20050182023A1/en
Priority to PCT/BR2003/000018 priority patent/WO2003066038A1/en
Priority to EP03737219A priority patent/EP1482923A1/en
Publication of BR0200751A publication Critical patent/BR0200751A/pt
Priority to US11/882,086 priority patent/US20080058284A1/en
Priority to PCT/BR2008/000023 priority patent/WO2009003255A1/en
Priority to CN200880101602A priority patent/CN101835470A/zh
Publication of BR0200751C1 publication Critical patent/BR0200751C1/pt
Publication of BRPI0200751B1 publication Critical patent/BRPI0200751B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Anesthesiology (AREA)
  • Communicable Diseases (AREA)

Abstract

Processo de preparação de formulações de semicarbazonas e/ou tiossemicarbazonas com ciclodextrinas e seus derivados e produtos obtidas desse processo. O presente Certificado de Adição decorrente do pedido de Patente de Invenção PI0200751-7, depositada em 06 de fevereiro de 2002, descreve novas composições farmacêuticas de semicarbazonas, tiossemicarbazonas, bem como seus derivados e misturas destes. Estas composições podem, opcionalmente, estar incluídas em sistemas de liberação controlada, a exemplo de ciclodextrinas e seus derivados. As referidas composições são úteis para o tratamento de condições inflamatórias ou dolorosas, bem como para o tratamento antitérmico, quando administradas por via oral ou parenteral.
BRPI0200751A 2002-02-06 2002-02-06 complexos de inclusão de benzaldeído semicabazona em ciclodextrinas e seu método de preparação BRPI0200751B1 (pt)

Priority Applications (9)

Application Number Priority Date Filing Date Title
BRPI0200751A BRPI0200751B1 (pt) 2002-02-06 2002-02-06 complexos de inclusão de benzaldeído semicabazona em ciclodextrinas e seu método de preparação
EP03737219A EP1482923A1 (en) 2002-02-06 2003-02-05 Process to prepare semicarbazones' and/or tiosemicarbazones' formulations using cyclodextrins and their derivatives and products obtained by this process
CA002475493A CA2475493A1 (en) 2002-02-06 2003-02-05 Inclusion complexes of semicarbazones into cyclodetrins and uses thereof
US10/503,735 US20050182023A1 (en) 2002-02-06 2003-02-05 Process to prepare semicarbazones' and/or tiosemicarbazones' formulations using cyclodextrins and their derivatives and products obtained by this process
PCT/BR2003/000018 WO2003066038A1 (en) 2002-02-06 2003-02-05 Process to prepare semicarbazones’ and/or tiosemicarbazones’ formulations using cyclodextrins and their derivatives and products obtained by this process
AU2003227141A AU2003227141A1 (en) 2002-02-06 2003-02-05 Process to prepare semicarbazones' and/or tiosemicarbazones' formulations using cyclodextrins and their derivatives and products obtained by this process
US11/882,086 US20080058284A1 (en) 2002-02-06 2007-07-30 Pharmaceutical compositions of semicarbazones and/or thiosemicarbazones and/or their derivatives and products of these compositions and their uses as anticonvulsant, anti-nociceptive and anti-inflammatory agents, and in the angiogenic therapy
PCT/BR2008/000023 WO2009003255A1 (en) 2002-02-06 2008-01-25 Pharmaceutical compositions comprising semicarbazones and thiosemicar-bazones and method for treating inflammatory, painful and febrile conditions and preventing signs and symptoms
CN200880101602A CN101835470A (zh) 2002-02-06 2008-01-25 包含缩氨基脲和缩氨基硫脲的药物组合物和治疗炎症、疼痛和发热病症和防止炎症体征及症状的方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0200751A BRPI0200751B1 (pt) 2002-02-06 2002-02-06 complexos de inclusão de benzaldeído semicabazona em ciclodextrinas e seu método de preparação

Publications (3)

Publication Number Publication Date
BR0200751A BR0200751A (pt) 2006-03-07
BR0200751C1 true BR0200751C1 (pt) 2008-07-01
BRPI0200751B1 BRPI0200751B1 (pt) 2018-10-23

Family

ID=27671852

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0200751A BRPI0200751B1 (pt) 2002-02-06 2002-02-06 complexos de inclusão de benzaldeído semicabazona em ciclodextrinas e seu método de preparação

Country Status (7)

Country Link
US (2) US20050182023A1 (pt)
EP (1) EP1482923A1 (pt)
CN (1) CN101835470A (pt)
AU (1) AU2003227141A1 (pt)
BR (1) BRPI0200751B1 (pt)
CA (1) CA2475493A1 (pt)
WO (2) WO2003066038A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0200751B1 (pt) * 2002-02-06 2018-10-23 Univ Minas Gerais complexos de inclusão de benzaldeído semicabazona em ciclodextrinas e seu método de preparação
US20100249238A1 (en) * 2007-07-02 2010-09-30 Ruben Dario Sinisterra Pharmaceutical compositions comprising semicarbazones and thiosemicarbazones and method for treating inflammatory, painful and febrile conditions and preventing signs and symptoms of inflammation
CA2720254A1 (en) * 2008-04-01 2009-12-17 Regents Of The University Of Colorado, A Body Corporate Methods and compositions for the intracerebroventricular administration of felbamate
WO2009139925A1 (en) * 2008-05-16 2009-11-19 Panacea Pharmaceuticals, Inc. Methods for the treatment of brain edema
US20120238604A1 (en) * 2009-09-04 2012-09-20 Molecular Discovery Systems Cytotoxic compounds
US20140287021A1 (en) * 2013-03-21 2014-09-25 Panacea Pharmaceuticals Treatment of chemotherapy-induced peripheral neuropathy
WO2017182873A2 (en) * 2016-04-19 2017-10-26 Ureka Sarl Peptide-oligourea foldamer compounds and methods of their use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2947526A1 (de) * 1978-11-29 1980-06-12 Ono Pharmaceutical Co Prostacyclin-analoge
GB9801109D0 (en) * 1998-01-20 1998-03-18 Pfizer Cyclodextrin compositions
EP1169060B1 (en) * 1999-04-09 2005-08-31 Euro-Celtique S.A. Sodium channel blocker compositions and the use thereof
BRPI0200751B1 (pt) * 2002-02-06 2018-10-23 Univ Minas Gerais complexos de inclusão de benzaldeído semicabazona em ciclodextrinas e seu método de preparação

Also Published As

Publication number Publication date
EP1482923A1 (en) 2004-12-08
WO2009003255A1 (en) 2009-01-08
CA2475493A1 (en) 2003-08-14
BRPI0200751B1 (pt) 2018-10-23
US20050182023A1 (en) 2005-08-18
AU2003227141A1 (en) 2003-09-02
CN101835470A (zh) 2010-09-15
US20080058284A1 (en) 2008-03-06
WO2003066038A1 (en) 2003-08-14
BR0200751A (pt) 2006-03-07

Similar Documents

Publication Publication Date Title
DE60314633D1 (de) Substituierte 1,3-diphenylprop-2-en-1-on derivate, deren herstellung und anwendungen
GT200100183A (es) Derivados de quinolina y quinazolina.
CY1118179T1 (el) Φαρμακευτικη συνθεση
BRPI0406883A (pt) Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
CY1113346T1 (el) Καινοφανη ενδιαμεσα προϊοντα χρησιμα στην παρασκευη της ενωσης του αλφα-(ν-σουλφοναμιδο)ακεταμιδιου
BR0112104A (pt) Processos para tratamento de doenças reumáticas usando uma molécula de ctla4 solúvel
CY1112962T1 (el) 1,2-διαρυλο βενζιμιδαζολες για την αντιμετωπιση ασθενειων, οι οποιες σχετιζονται με την ενεργοποιηση μικρογλοιων
WO2004080423A3 (en) 7-amino- isoindolyl compounds amd their pharmaceutical uses
NO20062303L (no) Pyrazinderivater og farmasoytisk anvendelse derav
BR0102040A (pt) Uso de paclitaxel estabilizado com albumina para preparação de uma droga para o tratamento de tumores sólidos e a droga desse modo obtida
WO2003096989A3 (en) Anti tubercular drug: compositions and methods
HUP0104709A2 (hu) Eritropoietin vagy eritropoietrinszármazékok alkalmazása agyi iszkémiák kezelésére használható gyógyszer előállítására
BRPI0407662B8 (pt) derivados do ácido 1-fenilalcanocarboxílico para o tratamento de doenças neurodegenerativas
BRPI0011867B8 (pt) preparação farmacêutica de levodopa/carbidopa/entacapona e processo para preparação da mesma
DE60336664D1 (de) Nichtnukleosidische reverse-transkriptase-hemmer
MXPA05014082A (es) Acidos biariloximetilarenocarboxilicos.
CY1106476T1 (el) Υποκατεστημενες διυδροκιναζολινες με αντι-ιικες ιδιοτητες
BR0013180A (pt) Oligonucleotìdeos para inibição da expressão de eg5 humano
BR0210122A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
BR0315169A (pt) Referência cruzada a pedidos de patente relacionados
BRPI0414428A (pt) composições farmacêuticas
BRPI0407234A (pt) Heterociclos substituìdos
EA200000836A1 (ru) Применение n-замещенных 1,5-дидезокси-1,5-имино-d-глюцитных производных для лечения инфекций, вызываемых вирусами гепатита
BRPI0507657A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para tratar um distúrbio, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo
CY1112591T1 (el) Απο του στοματος φαρμακοτεχνικες μορφες της κλαντριβινης

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: NAO CONHECIDO O PEDIDO DE INCLUSAO DE INVENTOR SOLICITADO NA PETICAO NO 000506/MG DE 10/03/2004, EM VIRTUDE DO DISPOSTO NO ART. 219, INCISO II DA LPI.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: PARA QUE SEJA ACEITA A PETICAO NO 014110000109/MG DE 14/01/2011 APRESENTE PETICAO DE DESARQUIVAMENTO DO PEDIDO, BEM COMO A RESPECTIVA RETRIBUICAO RELATIVA AO CUMPRIMENTO DE EXIGENCIA, EM VIRTUDE DO DISPOSTO NO ART. 33 UNICO DA LPI.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: REFERENTE 8A., 9A. E 10A. ANUIDADE(S).

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: REFERENTE AOS DESPACHOS PUBLICADOS NA RPI 2144 DE 07/02/2012 E RPI 2178 DE 02/10/2012.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A E 11A ABUIDADE CONFORME ART. 10 DA RES. 66/2013.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2217 DE 02/07/2013.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AOS DESPACHOS 8.6 NA RPI 2217 DE 02/07/2013 E 8.11 NA RPI 2250 DE 18/02/2014.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/10/2018, OBSERVADAS AS CONDICOES LEGAIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2552 DE 03-12-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL